Theriva Ev To Free Cash Flow from 2010 to 2024

TOVX Stock  USD 1.44  0.10  7.46%   
Theriva Biologics EV To Free Cash Flow yearly trend continues to be fairly stable with very little volatility. EV To Free Cash Flow is likely to outpace its year average in 2024. EV To Free Cash Flow is a valuation metric comparing Theriva Biologics' enterprise value to its free cash flow, used to evaluate whether Theriva Biologics is undervalued or overvalued. View All Fundamentals
 
EV To Free Cash Flow  
First Reported
2010-12-31
Previous Quarter
0.73445151
Current Value
0.77
Quarterly Volatility
94.04085926
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.5 K, Total Revenue of 0.0 or Other Operating Expenses of 13.9 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.17. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.
  
Check out the analysis of Theriva Biologics Correlation against competitors.
For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Latest Theriva Biologics' Ev To Free Cash Flow Growth Pattern

Below is the plot of the Ev To Free Cash Flow of Theriva Biologics over the last few years. It is a valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued. Theriva Biologics' EV To Free Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theriva Biologics' overall financial position and show how it may be relating to other accounts over time.
Ev To Free Cash Flow10 Years Trend
Slightly volatile
   Ev To Free Cash Flow   
       Timeline  

Theriva Ev To Free Cash Flow Regression Statistics

Arithmetic Mean(78.44)
Coefficient Of Variation(119.89)
Mean Deviation74.43
Median(59.17)
Standard Deviation94.04
Sample Variance8,844
Range303
R-Value0.67
Mean Square Error5,198
R-Squared0.45
Significance0.01
Slope14.17
Total Sum of Squares123,812

Theriva Ev To Free Cash Flow History

2024 0.77
2023 0.73
2022 1.73
2021 -59.17
2020 -14.48
2019 -13.98
2018 -3.37

About Theriva Biologics Financial Statements

Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' Ev To Free Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EV To Free Cash Flow 0.73  0.77 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.